The aligned vision of these two scalp cooling industry leaders will combine the unique strengths of both companies, positioned to accelerate these shared goals, whilst creating deeper, more meaningful impact.
The ongoing work in navigating the insurance reimbursement landscape in the United States remains a key priority. The undeniable synergistic value will enable Paxman to navigate and transform the evolving U.S. reimbursement landscape with greater agility and strength, expanding equitable patient access to the treatment. Starting in 2026, scalp cooling treatment will be assigned permanent CPT Category I codes. This is a key milestone that paves the way for broader insurance reimbursement, reducing the financial toxicity and burden of a cancer diagnosis that many patients across the U.S. currently face.
In addition, New York State recently became the first in the U.S. to pass a law requiring private insurers to cover scalp cooling, with further bills in progress in Louisiana, Maryland, Massachusetts, New Jersey, Rhode Island and West Virginia, this is an encouraging sign that momentum is building nationwide. Financial stress can be overwhelming during and after treatment, and increased access through insurance could make a meaningful difference in patients’ emotional well-being.
The merger creates favourable conditions for the introduction of the Paxman device specifically designed to prevent Chemotherapy-Induced Peripheral Neuropathy (CIPN) in cancer patients. As we approach commercialisation in Q2 2026, the urgent and largely unmet clinical need for effective CIPN prevention presents a significant opportunity to improve patient quality of life on a global scale. In preparation for the proposed product launch and rollout in H2 2026, the expansion of our U.S. team will enhance operational capacity and strengthen our presence in this key market.
Read the Regulatory Press Release
here.
